AHEAD Medicine’s AI platform removes bottlenecks in drug discovery, clinical trials and patient management, increasing speed, accuracy and reproducibility.
TAIPEI, July 28, 2022 /PRNewswire/ — AHEAD Medicine, a UC Berkeley SkyDeck-backed company, has launched a new AI-based cell immunoprofiling analytics platform. The platform unlocks the cellular-level data critical to vaccines, therapeutic research and development, patient diagnosis, and the safety of next-generation treatments such as cell therapy. The company will showcase its technology at US bio 2022.
Your 37 trillion cells hold secrets to your health. Hospitals and labs use machines called flow cytometers to examine the size, shape, age, and protein expression of your cells. Currently, manually converting this data at the cellular level into actionable clinical insights requires highly skilled people to visually interpret millions of data points at once. As a result, it is an expensive, error-prone bottleneck in advanced healthcare markets and simply unavailable in emerging markets.
AHEAD’s AI platform delivers immediate results, improving interpretation accuracy and repeatability at significant cost savings.
Andrea WangCEO and Co-Founder of AHEAD Medicinea cancer survivor with graduate experience in cancer research and data science, has always had a keen interest in applying AI to medicine.
Speaking of the company’s core technology, Cheek shares, “we have developed a fully automated analysis software platform where physicians or researchers simply upload raw cell analysis data from flow cytometry instruments. Our software instantly analyzes multiple samples at once and provides actionable insights in seconds.”
Roots in STEM Harbor Taiwan
Taiwan boasts a large pool of high-quality STEM talent, extensive expertise and a productive environment for conducting clinical trials, advanced bio-ICT capabilities and active collaboration between government, industry and academia in medical research .
AHEAD is a product of this system. Research teams from National Taiwan University Hospital and National Tsing Hua University, with the support of the Ministry of Science and Technology (MOST), developed and ultimately developed the technology behind AHEAD Medicine and its Taiwanese R&D subsidiary AHEAD Intelligence. Based on this collaboration, the startup has a broad patent portfolio.
From Taiwan to the rest of the world
AHEAD Medicine is currently expanding globally, with new US headquarters opened in California, and it is the first RUO product available for acute leukemia and lymphoma. With easy-to-use software that improves the efficiency, accuracy and reproducibility of cellular analysis, AHEAD is on track to make the next generation of science and treatment available to everyone.
AHEAD Medicine Disrupts Cell Analysis with AI to Help Accelerate Disease Diagnosis and Cell Therapy Worldwide
For more information, visit https://www.aheadmedicine.com
View original content to download multimedia: https://www.prnewswire.com/news-releases/taiwan-firm-ahead-medicine-disrupting-cell-analysis-with-ai-to-help-accelerate-disease-diagnostics- and -cell-therapy-worldwide-301595893.html
SOURCE AHEAD Medicine AHEAD Intelligence